Celgene Corp. (NASDAQ:CELG)‘s stock had its “market perform” rating reaffirmed by analysts at Leerink Swann in a note issued to investors on Wednesday. They presently have a $139.00 price objective on the biopharmaceutical company’s stock. Leerink Swann’s price target would suggest a potential upside of 17.29% from the company’s current price.

Several other research firms have also weighed in on CELG. Vetr lowered Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $115.50 price target on the stock. in a research report on Monday, October 31st. BTIG Research restated a “buy” rating and set a $138.00 price target on shares of Celgene Corp. in a research report on Sunday, August 21st. BMO Capital Markets restated an “outperform” rating and set a $141.00 price target on shares of Celgene Corp. in a research report on Monday, October 3rd. JPMorgan Chase & Co. restated an “overweight” rating and set a $136.00 price target on shares of Celgene Corp. in a research report on Friday, August 19th. Finally, Jefferies Group restated a “buy” rating and set a $134.00 price target on shares of Celgene Corp. in a research report on Monday, October 17th. Four equities research analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the company. Celgene Corp. presently has a consensus rating of “Buy” and a consensus target price of $136.77.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded down 2.96% during midday trading on Wednesday, hitting $118.51. The company had a trading volume of 5,512,285 shares. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $127.00. The stock has a 50 day moving average price of $108.88 and a 200 day moving average price of $106.73. The company has a market capitalization of $91.87 billion, a P/E ratio of 45.01 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.10. The firm had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The business’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $1.23 EPS. Equities analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

WARNING: This piece of content was reported by Financial Market News and is the propert of of Financial Market News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at http://www.financial-market-news.com/leerink-swann-reiterates-market-perform-rating-for-celgene-corp-celg/1211217/.

In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the firm’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the transaction, the director now directly owns 72,142 shares in the company, valued at approximately $7,678,794.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Corp /De/ Celgene acquired 800,150 shares of Celgene Corp. stock in a transaction on Monday, October 24th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. 0.97% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CELG. Arete Wealth Advisors LLC increased its position in Celgene Corp. by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 10 shares during the last quarter. Park National Corp OH increased its position in Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares during the last quarter. Proficio Capital Partners LLC increased its position in Celgene Corp. by 0.9% in the third quarter. Proficio Capital Partners LLC now owns 1,627 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15 shares during the last quarter. Reynders McVeigh Capital Management LLC increased its position in Celgene Corp. by 0.4% in the third quarter. Reynders McVeigh Capital Management LLC now owns 6,265 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 24 shares during the last quarter. Finally, Jolley Asset Management LLC increased its position in Celgene Corp. by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares during the last quarter. Institutional investors own 76.43% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.